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Abstract 
 
Background  
In a year when UK drug-related deaths and festival drug-related deaths reached their highest on 
record, a pilot festival drug safety testing service was introduced with the aim of reducing drug-
related harm. This paper describes the operational and behavioural outcomes of this pilot and 
explores the relationship between drug use, supply and policing within festival grounds. 
 
Methods  
Chemists in a temporary laboratory analysed 247 substances submitted by the public to a free, 
confidential testing service across four days at a UK festival in July 2016. Test results were returned 
to service users embedded in 230 healthcare consultations delivered to approximately 900 festival-
goers (one in five drug using festival-goers) that included harm reduction advice and the opportunity 
to use a disposal service for further substances of concern. Consultation data were collected at point 
of care, matched with test results, coded and analysed using SPSS.  
 
Results  
Test results revealed that one in five substances was not as sold or acquired. One in five service 
users utilised the disposal service for further substances of concern in their possession and another 
one in six moderated their consumption. Two thirds of those whose sample was missold disposed of 
further substances, compared with under one in ten whose sample was as sold. Service users who 
acquired substances onsite at the festival were more than twice as likely to have been missold them 
as those acquired offsite, were nearly twice as likely to use the disposal service and were on average 
two years younger. Women were more likely to be using the drug for the first time and more likely 
to use the disposal service. Test results were shared with emergency services; alerts issued across 
site and an unanticipated feedback loop occurred to some drug suppliers.  
 
Conclusion 
This pilot suggests that festival-goers engage productively with onsite drug safety testing services 
when given the opportunity, such services can access harder-to-reach and new user groups and can 
play a part in reducing drug-related harm by identifying and informing service users, emergency 
services and offsite drug using communities about substances of concern. Disposals to the testing 
service for onward police destruction provide an externally corroborated measure of impact, 
reducing harm to the individual and others by removing such substances from site. Evidence of 
differential dealing onsite and its potential negative consequences has implications for future 
research and policing. 
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Introduction 
 
Drug checking (drug safety testing, pill testing, street drug analysis) – a public health intervention 
that allows the general public to submit substances for content analysis – has existed for over 50 
years. The first wave of analysis of street drugs by community based drugs services was in late 1960s 
and early 1970s California, with the origins dated to San Francisco in 1965 (Marshman, 1974; Smith, 
1974). The second wave of drug safety testing occurred in 1990s Europe with the advent of acid 
house, rave and electronic dance music and the associated use of synthetic ‘party drugs’ such as 
MDMA at dance events. In 1992 a Dutch government-funded Drug Information and Monitoring 
System (DIMS) was established and similar services sprung up across Europe in subsequent years 
(Brunt, 2017; Kriener et al, 2001). A third wave of expansion occurred in the UK, North America and 
Australasia in recent years as new technologies and New Psychoactive Substances (NPS) emerged, 
making publicly accessible forensic testing for harm reduction purposes more feasible, more 
accurate and more pertinent. The international opioid overdose crisis and associated contamination 
of illegal drug markets with fentanyl and other analogues has added further impetus to 
consideration of this public health intervention (Tupper et al, 2018). 
 
A global review of drug checking services identified 31 services in operation in 20 countries in 2017, 
with DIMS the longest running (Barratt et al, 2018). In the UK, some public health (RSPH 2017) and 
police (WMPCC 2018) bodies have endorsed the measure. Such is the growing interest in drug 
checking that 31st March 2017 was declared the first ‘International Drug Checking Day’. Yet whilst 
the value of obtaining intelligence to monitor drug markets, assist emergency service provision and 
inform early warning systems is recognised, concerns have been expressed about a “limited” 
evidence base on the behavioural outcomes for individual service users from publicly accessible 
safety testing (EMCDDA, 2017: 139; see also Sumnall et al, 2017), and these are enhanced by 
concerns about potentially encouraging drug use by reducing health and criminal justice risks and 
their supposed deterrent value within an illegal market.  
 
There are a number of different models of drug safety testing with all at their core comprised of the 
forensic analysis of suspected psychoactive drugs to directly inform individual service users and in 
some cases wider stakeholders of the contents for harm reduction purposes. Variations in services 
relate to the primary purpose of the testing; who conducts the analyses and how; the range of 
quantitative or qualitative analytical methods used; who disseminates test results and how; where 
testing is located (such as mobile/ event-based or fixed site/ community-based); whether test results 
go directly to users or via an intermediary; and the varying levels of engagement and support from 
other stakeholder groups. At the Canadian Shambhala festival, for example, test results are not 
shared directly between the testing service and other onsite agencies such as police (Michelow and 
Dowden, 2015). By comparison, Multi Agency Safety Testing (MAST), the term coined by the author 
for the model of drug safety testing piloted in the UK (Measham, 2016), is distinctive in that firstly, it 
foregrounds the sharing of test results with onsite and offsite stakeholders with the agreed aim of 
reducing drug-related harm and secondly, test results are delivered by healthcare staff embedded in 
brief interventions (Fisher and Measham, 2018). UK stakeholders preferred the term ‘safety testing’ 
to ‘checking’ because of the latter’s association with a ‘checklist’, problematic in the UK legislative 
context where encouraging or assisting a crime is itself a crime in the Serious Crime Act 2007 
(https://www.legislation.gov.uk/ukpga/2007/27/part/2). ‘Safety’ testing emphasises the aim to help 
keep the public safe and distinguishes it from testing for surveillance purposes such as in prisons and 
workplaces. 
 
 
Controversies in Drug Safety Testing 
 
Advocates argue that drug safety testing can reduce drug-related harm and improve health and 
wellbeing at a number of levels from the micro (individual service users) and the meso (festivals, 
nightclubs and associated stakeholders) through to the macro (national and international). This can 
occur through accessing hidden or hard-to-reach populations not in touch with existing health 
services; providing an opportunity to engage in a dialogue about health and harm by embedding 
feedback of test results in healthcare consultations; facilitating onward referral to local drugs 
services; monitoring trends in drug use and drug markets; activating alerts for regional, national and 
international early warning systems; identifying and informing users, onsite and offsite stakeholders 
of substances of concern; and also identifying misselling, for example of NPS as established street 
drugs (eg. Benchop et al, 2002; Brunt et al, 2016; Vidal Giné et al, 2014; Vidal Giné et al, 2017). 
Uniquely, drug safety testing can make a crucial connection between the anticipated and actual 
contents of illegal drugs, to better understand illegal markets and retail practices, to target alerts to 
the most appropriate users, and to allow us to estimate “the nature and size of the discrepancy 
between what people think they are taking and what they are actually taking” (Barratt and Ezard, 
2016: 558). 
 
For critics, the inevitable compromises involved in conducting forensic analyses in challenging 
conditions within a temporary laboratory mean that drug safety testing “at best… gives an artificial 
‘shine of safety’” (Winstock et al 2001: 1139) and at worst can provide dangerously inadequate test 
results given the inevitable trade-off between speed, accuracy, reliability and portability of 
equipment (Brunt, 2017: 9). Further concerns include inter-individual user variability, tablet 
disintegration variability (Schneider et al, 2016), drug dealers using the service as a quality control 
measure; a focus on risky substances (particularly contaminants) at the expense of risky behaviours 
(such as bingeing and polydrug use); a limited evidence base regarding the causal relationship 
between information and behaviour change; a risk of reducing the deterrent value/increasing the 
appeal of illegal drugs by enhancing their perceived safety; the potential for non enforcement of 
drug controls within a police ‘tolerance zone’ to be the ‘thin end of the wedge’ to decriminalisation; 
and a broader, more nebulous concern about drug safety testing ‘normalising’ attitudes to drug use 
amongst the wider population.  
 
In terms of the existing evidence base, at the macro level, the value of monitoring drug trends and 
informing early warning systems is evident in the substantial data collected at national (eg. by DIMS) 
and international level (eg. Brunt et al, 2016; EMCDDA, forthcoming). In his consideration of two 
decades of DIMS testing, Brunt (2012) argued that testing and associated public health alerts had 
not had a perverse impact on either drug use or drug-related deaths, with Dutch drug prevalence 
and mortality rates remaining both fairly stable and also favourable relative to other European 
countries. In the Netherlands in December 2014, for example, DIMS tested pink ‘Superman’ logo pills 
found to contain 173mg PMMA, issued immediate red alerts on national television and no deaths 
occurred. In the UK by comparison, without a national testing service or pre-emptive alerts from the 
authorities, four people died after taking similar pink ‘Superman’ pills containing PMMA within a 
fortnight of the DIMS alert (Nutt, 2015; Sample, 2015). Overall there is no evidence that drug 
prevalence, initiation or mortality rates have increased in European countries with drug safety 
testing by comparison with those without (Benschop et al, 2002; Brunt, 2012; Hungerbuehler et al, 
2011).  
 
At the micro level, evaluations have focused on either process or behavioural outcomes (Kriener et 
al, 2001). A key behavioural outcome measure is whether service users intend to consume or 
dispose of further substances in their possession after hearing their test result, particularly if the 
result was different to expected. The limited research to date on behavioural outcomes estimates 
disposal rates ranging from 4 to 76% according to a review by Leece (2017).  
 
Service user disposal rates have been measured by intentions after hearing test results (Kriener and 
Schmid, 2002; Makkai et al, 2018; Martins et al, 2017; Saleemi et al, 2017); self-reported historical 
recall (Van de Wijngaart et al 1999); hypothetical intentions into the future (Benschop et al, 2002; 
Black et al, 2008; Day et al, 2018; Dundes, 2003, Dunn et al, 2007; Johnston et al, 2006; Michelow 
and Dowden, 2015; Wiese and Verthein, 2014); or actual disposal rates immediately after hearing 
test results (Mema et al, 2018; Sage, 2015). This last measure is the strongest of these four 
behavioural indicators and was used in this pilot. Furthermore it allows external corroboration of 
actual disposal. 
 
This paper provides data and analysis from a free, confidential and non judgmental testing service 
delivered across four days at a 25,000 person capacity ‘boutique’ outdoor music festival by a non 
profit NGO in July 2016. Consideration is given here to the operational success of the pilot, 
measuring behavioural outcomes and exploring the impact of the illegal drug trade and its policing 
within the festival grounds. The broader context to this pilot was a heightened concern in the UK 
about increased drug-related deaths: including both the highest drug-related death rates on record 
and the highest in Europe that year (ONS, 2017). Furthermore, specifically in relation to this user 
group, 2016 saw the highest festival drug-related death rate on record (six deaths) and the highest 
MDMA and cocaine-related death rates on record in the UK (ONS, 2017). 
 
 
Methods 
 
Given that this was the first pilot of a drug safety testing service direct to the public in the UK 
(Brooks, 2016; UK Focal Point on Drugs, 2017: 156), the decision was taken to advertise the service 
neither beforehand nor liberally onsite. The service was located in a large fixed tent in a designated 
welfare area alongside festival welfare, paramedic and psychedelic support services, between the 
entertainment and camping fields, in a police-negotiated ‘tolerance zone’. The tent was divided in 
two by an opaque screen, with a front desk and individual ‘consultation booths’ accessible to the 
public, then behind the screen was a pop-up laboratory accessible only to staff. Signage at the tent 
was implicit, with the availability of onsite testing spreading predominantly by word of mouth 
through welfare, medical, hospitality and general staff, as well as through artists and management 
on and off stage.  
 
Members of the public could bring any substances of concern for testing and receive results as part 
of an individually tailored brief intervention by healthcare staff. The service operated by service 
users putting a dose – a pill or approximately 5mg of powder, but not vegetable or fungal matter – 
into a small plastic bag which they sealed and posted in a locked amnesty bin that was regularly 
taken and emptied in the lab. They received a unique ID number and were asked to return about an 
hour later. Opening hours were approximately midday to 8pm from Thursday to Sunday with peak 
usage at around 4pm. Volunteer post graduate (predominantly post doctoral) chemists used a series 
of up to three analytical techniques with results triangulated where appropriate: firstly, Fourier 
Transfer Infrared (FTIR) spectroscopy whereby sample spectra are algorithmically compared with 
reference library spectra (using the TICTAC ATR FTIR and Bruker ATR FTIR Library in the OPUS 7.5 
software running the ‘Default’ algorithm); secondly, colorimetric reagent tests (to identify heavily 
diluted substances or those that might not be identified by FTIR); and thirdly, mass loss analysis, a 
wet chemical process using solvent washing to extract binders to allow approximate measurement 
MDMA content in ecstasy pills (for comparison of analytic techniques see Brunt, 2017; Kerr and 
Tupper, 2018; Kriener et al, 2001). 
 
The testing service delivered 230 brief interventions, with forensic test results not collected for 
another 17 submitted samples. Consultation data were electronically recorded by healthcare staff at 
point of care for the nominated primary service user, matched with forensic test data recorded by 
chemists in the lab, then coded and analysed using SPSS 22. The pilot revealed that service users 
visited the testing service on average in friendship groups of four therefore resulting in harm 
reduction advice embedded in the local drug market context being distributed directly to 
approximately 900 service users. This equates to approximately one in five drug users at that 
festival, based on the UKFA (2017) estimate of 20.9% of UK festival-goers taking illegal drugs.  
 
Consultations lasted approximately 15/20 minutes and followed a predetermined structure. This 
included a pre-scripted general warning about all drug use carrying risks and drug use not being 
encouraged or facilitated by the service; demographics; medical and drugs histories; current use of 
alcohol, drugs and medications; what the sample was bought as, thought to be and test revealed it 
to be; analytical and batch-specific limitations; as well as harm reduction advice tailored to the 
individual(s) and their consultation. Risky behaviours such as bingeing, polydrug use and specific 
drug combinations of concern were also discussed. Additionally there were opportunities for 
questions; free harm reduction leaflets; and onwards signposting to a local drugs service. Finally, all 
service users were offered the opportunity to use a disposal service whereby further substances of 
concern in their possession could be handed over for onward safe destruction by the police. Passing 
substances to a testing service for onward police destruction operates in a similar legal terrain in the 
UK to festival security staff confiscating drugs where the primary purpose is to “deliver it into the 
custody of a person lawfully entitled to take custody of it” 
(http://www.legislation.gov.uk/ukpga/1971/38/section/5).  
 
Festival-goer commitment to obtaining information about substances of concern was evident not 
only in queues to use the service throughout the four days of the festival but also in the higher-than-
anticipated demand on the last day to find out more about substances consumed earlier that 
weekend. For example, one young woman who was hospitalised on Saturday night returned to the 
festival on Sunday especially to get a sample tested to try to find out more about what might have 
prompted her hospital admission. Overall, over four in ten MAST service users reported having 
general or specific concerns about their sample or their own health and wellbeing. These included a 
quarter (25.2%) having concerns about that particular sample (including already having experienced 
negative effects such as vomiting, ‘bad trips’ and ‘allergic reactions’ at the festival), 14.8% reporting 
that they or their friends had experienced negative effects from that drug in the past, and 4.3% 
having general concerns about how they were feeling at the time of presentation.  
 
 
Results 
 
1. Sample 
 
The 230 MAST primary service users comprised 66% male, 87% White by self defined ethnic identity, 
with an average age of 27.6 years (median 26, standard deviation 7.5), ranging from 16 to 51. 
Ketamine service users were younger (24.2 years) than MDMA (27.8 years) and cocaine (27.5 years) 
users, as were female (25.3 years) compared with male (28.7 years) service users. By comparison, 
the UK WEDINOS (2017) postal drug testing service users comprised 87% male with an average age 
of 32.  
 
Just 5.2% of MAST primary service users reported previously having accessed support or treatment 
from a healthcare professional for their drug or alcohol use (eleven men and one woman, 7.2% v 
1.3%). Regarding initiation, 8.3% had never used that drug before, with a higher proportion of 
female than male first time users of that drug (11.7% v 6.5%).  
 
2. Forensic test results 
 
[Table 1 about here] 
 
Half (50%) of MAST service users bought or acquired their substance off site and successfully 
smuggled it past security search procedures at entry whereas 48.3% bought or acquired their 
substance from a friend, acquaintance or dealer within the festival grounds. Tests revealed that 37% 
of samples were MDMA crystal/powder, 20% ecstasy pills, 13.5% ketamine and 10% cocaine (see 
Table 1), with nearly one in five samples (19.5%) at variance with what they were sold as. Substances 
acquired within the festival grounds were more than twice as likely to be at variance with what they 
were sold as compared with those bought offsite (27% v 12%, p<.01), with service users buying 
within the festival approximately two years younger than those buying offsite (26.5 years v 28.5 
years old). In terms of missold substances, (i) some samples were revealed to be cheaper 
psychoactive drugs missold as more expensive drugs, for example ketamine missold as cocaine (up 
to double the street price and greater criminal penalties in the UK, resulting in a higher reward to 
risk ratio for a dealer); and cathinones missold as cocaine, ketamine and MDMA, including one 
sample of n-ethyl pentylone, a longlasting cathinone, missold as MDMA (Measham and Jones, 2017). 
(ii) A number of samples contained pharmaceuticals and cutting agents including chloroquine (a 
prescription anti malaria medicine), benzocaine, caffeine, ephedrine and paracetamol all missold as 
cocaine. (iii) Other missold samples contained inactive but relatively harmless ingredients such as six 
samples of plaster of paris missold as ecstasy pills and four samples of brown sugar missold as 
MDMA crystal. 
 
[Table 2 about here] 
 
3. Individual Behavioural Outcomes 
 
The provision of a disposal service for onward police destruction provided an externally 
corroborated indicator of positive engagement with the service, as well as removing substances of 
concern from circulation and eliminating the risk of disposals becoming ‘ground finds’ that could 
harm other adults, children or animals onsite. Upon hearing the test result, over one in five service 
users (21.3%) chose to use the disposal service (see Table 2 for further details on disposals). Two 
thirds of those whose test result revealed their sample to be at variance with what it was sold as 
then handed over further substances in their possession compared with under one in ten whose 
sample was confirmed to be as sold (66.7% v 9.1%, p<.01). Those who obtained their sample within 
the festival grounds were nearly twice as likely to use the disposal service as those who obtained 
their sample offsite (27% v 14.8%, p <.05), with a quarter of women compared with one in five men 
utilising the disposal service (24.7% v 19.6%). 
 
[Table 3 about here] 
 
Twenty two MAST service users (8%) said that they would take the substance over a longer time 
period or after leaving the festival and another seven said that they intended to take a smaller 
quantity of the drug (see Table 3 for further breakdown of individual outcomes). For most of these 
their test result confirmed the substance to be as sold but of a higher strength than anticipated, with 
the consultation session providing an opportunity for healthcare staff to discuss estimated strength 
and appropriate dosage. Six respondents reported their intention to throw away further substances 
in their possession after hearing the test result. It is reasonable to presume that some festival-goers 
will enter a testing service with just one dose to test and keep the rest of their supplies in their tent 
for fear of arrest and whilst some might return to utilise the NGO disposal service, others will discard 
unwanted substances in any convenient nearby refuse bin. 
 
Two service users requested signposting to local drugs services when offered, neither of whom had 
previously been in touch with drugs services. A further two service users reported planning to return 
their drugs to their dealer to inform them about unwanted contents and/or to ask for a refund. Drug 
safety testing therefore could stimulate an interesting accountability feedback ‘loop’ between drug 
dealers and their regular customers.  
 
4. Meso level impact: alerts, drug-related deaths and hospital admissions 
 
All onsite agencies at the festival – including police, welfare, security and paramedical services – 
were provided with updates on MAST test results at daily security advisory group meetings. Testing 
revealed significant misselling onsite, prompting the circulation of targeted alerts with the support 
of festival management and police, including for chloroquine and ketamine missold as cocaine, and 
for high MDMA content pills. 
 
Given use of the disposal service and other reported positive harm reduction intentions (such as 
lower dosage, taking over a longer time period, see Table 3), one might anticipate a reduction in 
drug-related medical incidents onsite. A reduction in drug-related deaths could be considered a clear 
measure of positive behavioural outcomes and indeed mortality rates have been used as a key 
measure of drug-related harm for example, in Nutt et al’s (2010) multi criteria decision analysis 
modelling. There were six drug-related deaths at UK festivals in 2016, the highest on record, but 
none at the pilot festival that year. However, drug-related deaths are both relatively rare at festivals 
and often multi factoral. Therefore a more useful measure of efficacy is hospital admissions for drug-
related medical incidents that require major critical care, data that are usually recorded by the 
festival paramedical service and at this festival were collated by the multi agency harm reduction 
lead (Ward, 2016).  
 
This festival reported a 95% reduction in drug-related hospital admissions in 2016 (the year that 
MAST was introduced) compared with the previous year. There were 19 drug-related hospital 
admissions of 59 in total in 2015 (similar to previous years), by comparison with only one drug 
related hospital admission of 50 in total in 2016 (Ward, 2015, 2016). Festival and partner agencies 
suggested a number of possible explanations for this fall: MAST raised awareness of contaminants in 
circulation and misselling onsite, with alerts circulating via social media and word of mouth from 
medical, welfare and general staff, and festival-goers. If each service user (approximately one in 25) 
who received a harm reduction consultation then spoke with five friends, not unreasonable given 
the excitement surrounding participating in the UK’s first drug safety testing pilot, and if, according 
to UKFA (2017), an estimated one in five festival-goers take illegal drugs at UK festivals, then blanket 
saturation could have been reached for localised alerts and associated harm reduction advice at this 
festival. This reach - festival paramedics, management, welfare and police concurred - led to early 
presentation for drug-related problems combined with a greater confidence amongst paramedics in 
treating drug-related presentations onsite rather than sending them to hospital.  
 
 
Discussion 
 
This paper describes the UK’s first drug safety testing service direct to the public, conducted to 
assess the feasibility, practicality and efficacy of delivering festival testing. The pilot established that 
positive engagement was possible from all key stakeholders including police, public health, local 
authorities and event management, as well as providing an opportunity to access and engage 
directly with harder to reach and first time drug using groups. Festival-goers were willing to submit 
substances of concern for analysis and to engage productively in healthcare consultations when 
offered the opportunity. Harm reduction messages informed by test results, medical and drugs 
histories were delivered directly to approximately one in five drug using festival-goers, with a word-
of-mouth ripple effect resulting in potential blanket saturation of messaging to that population. 
MAST service users reported their intention to take smaller quantities of substances, over a longer 
time period and to be more careful about polydrug combinations, with a small number also 
requesting signposting to drugs services to continue a dialogue with healthcare professionals after 
the festival.  
 
Nearly one fifth of submitted substances was missold and two thirds of these service users handed 
over further substances of concern in their possession to the MAST disposal service for onward safe 
police destruction, thereby reducing the risk of harm to others from discarded substances, as well as 
providing an externally corroborated measure of impact. A larger proportion of female than male 
service users were first time consumers of the submitted substance, had not previously spoken with 
healthcare professionals and then went on to utilise the disposal service, contrasting with women’s 
lower representation in traditional drugs services (Simpson and McNulty, 2008). Whilst this pilot 
cannot ascertain any contribution of MAST towards reduced drug-related hospital admissions as 
there was no opportunity to control for other important variables associated with hospitalisations, 
nevertheless, there was only one drug-related hospital admission from this festival in 2016, a 95% 
reduction on previous years. 
 
Brief interventions to service users and alerts to festival-goers informed them of localised misselling 
onsite, potentially reducing demand for those substances and facilitating a feedback loop to dealers. 
Other researchers have noted the potential for drug safety testing to impact positively on illegal drug 
markets with red alerts reducing demand to the point where a drug leaves the market (eg. Spruit, 
2001). Testing services in Berlin and Switzerland, for example, have reported that tested pills have 
increasingly corresponded to expectations over time, suggesting that drug safety testing could have 
a positive impact on these illegal drug markets (Kriener et al., 2001). Ritter (2005) warns, however, 
that a trend in improved “quality” cannot necessarily be attributed directly to drug safety testing. 
The significant increase in purity of most illegal drugs in the UK, for example, happened around 2010 
onwards, six years before drug safety testing was introduced (UK Focal Point on Drugs, 2017: 176). 
 
Not only did this pilot illustrate drug safety testing’s potential value as a public health intervention 
but also to understand the operation of local drug markets and to inform the policing of festivals. In 
the MAST pilot, half of service users chose to buy drugs within the festival grounds. This may have 
been because of less easy access to drug dealers before entry, perhaps related to being a couple of 
years younger. However recent studies (Grigg et al, 2018; Hughes et al, 2017) suggest that high 
visibility policing and drug detection dogs at entry can drive some people to buy drugs within festival 
grounds rather than before entry. This drug safety testing pilot highlights the negative consequences 
of this drive to buy onsite in that substances bought onsite were more than twice as likely to be 
missold as those bought offsite and were nearly twice as likely to be disposed of at the MAST 
disposal service, suggesting that entry security procedures combined with onsite dealing practices 
could significantly increase drug-related harm. Future research on drug safety testing could usefully 
explore not only its efficacy in terms of harm reduction, therefore, but also its potential value in 
increasing our understanding of perceptions of risk, festival drug supply and use, and the policing of 
festivals. 
 
 
Pilot limitations and future directions 
 
Firstly, brief interventions were delivered in non ideal conditions, despite every effort being made to 
strive for productive engagement at point of care. For example, the service operated from 12-8pm in 
order to minimise intoxication levels of service users, closing before evening festivities got 
underway. Any service user assessed by healthcare staff to be intoxicated, unable to fully engage in 
the intervention and potentially unable to give informed consent was asked to return after a suitable 
time period. Nevertheless 62.9% of service users reported having already had an alcoholic drink (on 
average 4.3 UK units of alcohol) and 43% had already consumed drugs other than alcohol before 
using the service that day, reflecting levels of afternoon consumption at UK festivals.  
 
Secondly, the pilot revealed challenges in attempting to assess the efficacy of a drug safety testing 
service particularly at meso level. In order to assess the impact on hospital admissions, welfare and 
medical incidents, this requires data sharing with onsite and offsite partner agencies. However, data 
vary in quality, with year-on-year variations in agencies employed and indicators used, including 
some data failing to distinguish between ‘drug-related’ and ‘non drug-related’ indicators or between 
alcohol and drug-related intoxication. High quality stakeholder data collection is integral to high 
quality drug safety testing service evaluation. 
 
Thirdly, relatedly, future studies should monitor potential unintended consequences for both the 
legal and illegal drug markets from delivering a drug safety testing service, including displacement to 
other drugs including alcohol, the latter discussed anecdotally by some service users after hearing 
their test results. However, given that all service users had acquired and either intended to consume 
or already had consumed the substance they submitted for testing, it is unlikely that prevalence of 
illegal drug use would increase significantly as a result of the service. Furthermore, given that over 
four in ten MAST service users had general or specific concerns about the sample or their own 
condition, one fifth of samples had been missold and over a quarter of the substances acquired 
onsite were missold, testing is more likely to have a deterrent than stimulant effect on drug supply 
and use within the festival grounds. 
 
 
  
References 
 
Barratt, M., Kowalski, M., Maier, L., & Ritter, A. (2018), Global review of drug checking services 
operating in 2017, Drug Policy Modelling Program Bulletin No. 24. Sydney: National Drug & 
Alcohol Research Centre, UNSW.  
Barratt, M. J., & Ezard, N. (2016), Drug checking interventions can track the nature and size of the 
discrepancy between self-report and actual drugs consumed, Addiction, 111, 558-559. 
Benschop, A., Rabes, M., & Korf, D. (2002), Pill testing, Ecstasy and Prevention. A scientific evaluation 
in three European cities, Amsterdam: Rozenberg Publishers. 
Brooks, L. (2016), Secret Garden Party pioneers drugs testing service for festivalgoers, The Guardian, 
24th July, https://www.theguardian.com/society/2016/jul/24/secret-garden-party-pioneers-
drugs-testing-for-festival-goers  
Brunt, T. (2012), Monitoring illicit psychostimulants and related health issues, PhD, University of 
Amsterdam. 
Brunt, T. (2017), Drug checking as a harm reduction tool for recreational drug users: opportunities 
and challenges, Background paper commissioned by the EMCDDA for Health and social 
responses to drug problems: a European guide, Lisbon: EMCDDA. At:  
http://www.emcdda.europa.eu/system/files/attachments/6339/EuropeanResponsesGuide2017_Bac
kgroundPaper-Drug-checking-harm-reduction_0.pdf  
Brunt, T. and Niesink, R. (2011), The Drug Information and Monitoring System (DIMS) in the 
Netherlands: Implementation, results, and international comparison, Drug testing and 
Analysis, 3 (9): 621-634. 
Brunt, T., Nagy, C., Bucheli, A., Martins, D., Ugarte, M., Beduwe, C. and Vilamala, M. (2016), Drug 
testing in Europe: Monitoring results of the Trans European Drug Information (TEDI) project, 
Drug Testing and Analysis, 9 (2), 188-198. 
Day, N., Criss, J., Griffiths, B., Gujral, S., John-Leader, F., Johnston, J. and Pit, S. (2018), Music festival 
attendees’ illicit drug use, knowledge and practices regarding drug content and purity: a 
cross-sectional survey, Harm Reduction Journal, 15 (1): 1-8. 
European Monitoring Centre for Drugs and Drug Addiction, (2017), Health and social responses to 
drug problems: A European guide, Lisbon: EMCDDA. 
European Monitoring Centre for Drugs and Drug Addiction, (forthcoming), Trans-European Drug 
Information project (TEDI) activity report, Lisbon: EMCDDA. 
Fisher, H. and Measham, F. (2018), Night Lives, APPG, Durham University, The Loop and Volteface. 
At: http://volteface.me/app/uploads/2018/07/Night-Lives-PDF.pdf 
Grigg, J., Barratt, M. and Lenton, S. (2018), Drug detection dogs at Australian outdoor music festivals: 
Deterrent, detection and iatrogenic effects, International Journal of Drug Policy, 60: 89-95. 
Hughes, C., Moxham-Hall, V., Ritter, A., Weatherburn, D. and MacCoun, R. (2017), The deterrent 
effects of Australian street-level drug law enforcement on illicit drug offending at outdoor 
music festivals, International Journal of Drug Policy, 41: 91-100. 
Hungerbuehler, I., Buecheli, A., & Schaub, M. (2011), Drug Checking: A prevention measure for a 
heterogeneous group with high consumption frequency and polydrug use. Evaluation of 
Zurich's Drug Checking services, Harm Reduction Journal, 8 (1), 16. 
Jamieson, D. (2018), Reducing Crime and Preventing Harm: West Midlands Drug Policy 
Recommendations, Birmingham: West Midlands Police and Crime Commissioner. 
Johnston, J., Barratt, M., Fry, C., Kinner, S., Stoové, M., Degenhardt L., et al (2006), A survey of 
regular ecstasy users’ knowledge and practices around determining pill content and purity: 
Implications for policy and practice, International Journal of Drug Policy, 17 (6): 464-72.  
Leece, P. (2017), Evidence Brief: Drug checking services as a harm reduction intervention, Ontario 
Agency for Health Protection and Promotion (Public Health Ontario), Toronto: Queen’s 
Printer for Ontario. 
Kerr, T. and Tupper, K. (2017), Drug checking as a harm reduction intervention: Evidence Review 
Report, Vancouver: British Columbia Centre on Substance Use. 
Kriener, H., Billeth, R., Gollner, C., Lachout, S., Neubauer, P. and Schmid, R. (2001), An inventory of 
on-site pill-testing interventions in the EU, Lisbon: EMCDDA. 
Kriener, H. and Schmid, R. (2002), Check your pills. Check your life. ChEck it!! High quality on-site 
testing of illicit substances: Information counselling and safer use measures at raves in 
Austria, Vienna: CheckIT!. 
Makkai, T., Macleod, M., Vumbaca, G., Hill, P., Caldicott, D., Noffs, M., Tzanetis, S., and Hansen, F. 
(2018), Report on the ACT GTM Pill Testing Pilot: A Harm Reduction Service, Harm Reduction 
Australia.  
Marshman, J. (ed), (1974), Street Drug Analysis and its Social and Clinical Implications, International 
Symposia on Alcohol and Drug Addiction, Ontario: Addiction Research Foundation.  
Martins, D., Barratt, M., Pires, C., Carvalho, H., Vilamala, M., Espinosa, I. and Valente, H. (2017), The 
detection and prevention of unintentional consumption of DOx and 25x-NBOMe at 
Portugal’s Boom Festival, Human Psychopharmacology: Clinical and Experimental, 32: e2608. 
Measham, F. (2016), Drugs, Dissociatives and Displacement: The Festival Drug Report – Part II. 
Volteface, 21st July. http://volteface.me/features/the-festival-drug-report-part-ii/ 
Measham, F. and Jones, G. (2017), Pentylone: What is it, why should we care and how can Multi 
Agency Safety Testing help? Volteface, 4th August, http://volteface.me/features/pentylone-
care-can-multi-agency-safety-testing-help/  
Mema, S., (2018), Drug checking at an electronic dance music festival during the public health 
overdose emergency in British Columbia, Canadian Journal of Public Health,  
Michelow, W. and Dowden, C. (2015), “Start Small, Take it Easy”. Results from the ANKORS Harm 
Reduction Survey at the 2013 Shambhala Music Festival, Vancouver: University of British 
Columbia. At: 
http://www.ankorsvolunteer.com/uploads/4/6/9/3/46939087/ankors_2013_shambhala_su
rvey_report.pdf 
Nutt, D. (2015), The Superman pill deaths are the result of our illogical drugs policy, The Guardian, 
5th January. At: https://www.theguardian.com/commentisfree/2015/jan/05/superman-pill-
ecstasy-pma-deaths-drugs-policy 
Nutt, D., King, L. and Phillips, L. (2010), Drug harms in the UK: a multicriteria decision analysis, The 
Lancet, 376 (9752): 1558–1565. 
Office for National Statistics (ONS), (2017), Deaths related to drug poisoning in England and Wales: 
2016 registrations. Statistical Bulletin. At: 
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/death
s/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2016registrations  
Ritter, A. and Cameron, J. (2005), A systematic review of harm reduction, Drug Policy Modelling 
Project Monograph no. 6, Melbourne: Turning Point. 
Royal Society for Public Health (2017), Drug Safety Testing at Festivals and Nightclubs, London: 
RSPH. https://www.rsph.org.uk/about-us/news/let-festival-goers-and-clubbers-test-their-
drugs-to-reduce-harm.html 
Sage, C. (2015), Harm Reduction and Drug Checking: A wrap‐around service for festivals. Case Study: 
Shambhala Music Festival/ ANKORS Drug Checking Harm Reduction, Service data 2015, 
Nelson: ANKORS. At:  
http://www.ankorsvolunteer.com/uploads/4/6/9/3/46939087/sham_2015_report_-_pdf.pdf 
Saleemi, S., Pennybaker, S., Wooldridge, M. and Johnson, M., (2017), Who is ‘Molly’? MDMA 
adulterants by product name and the impact of harm-reduction services at raves, Journal of 
Psychopharmacology, 31 (8): 1056-1060. 
Sample, I. (2015), ‘Superman’ pill deaths spark calls for dangerous-drugs alert system, The Guardian, 
16th January. At: https://www.theguardian.com/society/2015/jan/16/superman-pill-deaths-
dangerous-drugs-alert-system 
Schneider, J., Galettis, P., Williams, M., Lucas, C., & Martin, J. (2016), Pill testing at music festivals: 
can we do more harm? International Medicine Journal, 46 (11): 1249-1251. 
Simpson, M. and McNulty, J. (2008), Different needs: Women's drug use and treatment in the UK, 
International Journal of Drug Policy, 19 (2): 169-175. 
Smith, D. E. (1974). Street drug analysis and community based drug programs. Journal of Psychedelic 
Drugs, 6 (2), 153-159. 
Spruit, I. (2001). Monitoring synthetic drug markets, trends, and public health, Substance Use and 
Misuse, 36 (1-2): 23-47. 
Sumnall, H., Bates, G. and Jones, L. (2017), Evidence review summary:  drug demand reduction, 
treatment and harm reduction, Background paper commissioned by the EMCDDA for Health 
and social responses to drug problems: a European guide, Lisbon: EMCDDA. 
Tupper, K., McCrae, K., Garber, I., Lysyshyn, M. and Wood, E. (2018), Initial results of a drug checking 
pilot program to detect fentanyl adulteration in a Canadian setting, Drug and Alcohol 
Dependence, 190: 242-245. 
UK Festival Awards (UKFA), (2017), Market Report 2017. At  
https://www.festivalawards.com/wp-content/uploads/2017/07/UKFA_MarketReport_17_lr.pdf 
UK Focal Point on Drugs, (2017), United Kingdom Drug Situation: Focal Point Annual Report 2017, 
London: PHE. At: 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_
data/file/713101/Focal_Point_Annual_Report.pdf 
Van de Wijngaart, G., Braam, R., de Bruin, D., Fris, M., Maalste, N. and Verbraeck, H. (1999), Ecstasy 
use at large-scale dance events in the Netherlands, Journal of Drug Issues, 29: 679–702. 
Vidal Giné, C., Espinosa, I., & Vilamala, M. (2014), New psychoactive substances as adulterants of 
controlled drugs. A worrying phenomenon? Drug Testing and Analysis, 6, 819-824. 
Vidal Giné C., Vilamala M., Measham F., Brunt T., Bücheli A, Paulos, C. et al (2017), The utility of drug 
checking services as moitoring tools and more: A response to Pirona et al, International 
Journal of Drug Policy, 45: 46-47. 
Ward, S. (2016), Post Report: Partnership Harm Reduction Plan Secret Garden Party 2016, 
Cambridge: Cambridgeshire Constabulary. Unpublished report. 
Ward, S. (2015), Post Report: Cambridgeshire Constabulary Harm Reduction Strategy Secret Garden 
Party 2015, Cambridge: Cambridgeshire Constabulary. Unpublished report. 
WEDINOS, (2017), PHILTRE Annual Report 1st Oct 2016-30th Sept 2017, Cardiff: Public Health Wales. 
 
 
  
 
 
Table 1: Test results for MAST submissions, festival pilot, 2016. 
 
Drug Count of results % 
MDMA  131 57% 
Ketamine 31 13.5% 
Cocaine 23 10% 
Cutting agents 16 7% 
Cathinone NPS 8 3.5% 
Unidentified 6 2.6% 
Plaster of paris 6 2.6% 
NPS 3 1.3% 
Pharmaceuticals 2 0.9% 
LSD 2 0.9% 
Amphetamines 2 0.9% 
Total  230 100 
 
Cutting agents = sugar (4), caffeine (3), chloroquine (3), caffeine/ephedrine (2), benzocaine (1), 
paracetamol (1), procaine (1), alum (1) 
Plaster of paris = calcium sulphate hemihydrate 
 
 
Table 2: Comparison of using the disposal service for onward police destruction by whether the 
sample matched what it was identified as when sold or given to the service user, 2016 
 
 Police destruction Other outcomes Total 
n 
% 
Matched sold as 15 
6.5% 
9.1% 
149 
64.8% 
90.9% 
164 
71.3% 
100% 
Didn’t match sold as 30 
13% 
66.7% 
15 
6.5% 
33.3% 
45 
19.6% 
100% 
Don’t know eg. ground finds 4 
1.7% 
19% 
17 
7.4% 
81% 
21 
9.1% 
100% 
Total 49 
21.3% 
181 
78.7% 
230 
100% 
 
NB ‘Matched sold as’ is distinguished here from service user expectations after having bought and 
possibly tried the substance. 
 
 
  
 
Table 3: Individual behavioural outcomes of 230 MAST brief interventions, 2016 – answers over 1% 
 
 Matched 
sold/acquired as 
Did not match 
sold/acquired as 
Other eg. 
ground find 
Total 
I will take my usual amount 111 
67.7% 
4 
8.9% 
6 
28.6% 
121 
52% 
Further substances handed 
for police destruction 
15 
9.1% 
30 
66.7% 
4 
19% 
49 
21.3% 
I may take it later/ over 
longer time period 
20 
12.2% 
1 
2.2% 
1 
4.8% 
22 
8% 
I will take smaller amount 7 
4.3% 
0 
0% 
0 
0% 
7 
3% 
I will throw it away myself 1 
0.6% 
4 
8.9% 
1 
4.8% 
6 
2.6% 
I will return it to my dealer 1 
0.6% 
1 
2.2% 
0 
0% 
2 
0.9% 
I will be more careful about 
mixing with other drugs 
1 
0.6% 
0 
0% 
0 
0% 
1 
0% 
None left 2 
1.2% 
1 
2.2% 
0 
0% 
3 
1.3% 
No answer given  6 
3.7% 
4 
8.9% 
9 
42.9% 
19 
8.3% 
Total 164 
100% 
71.3% 
45 
100% 
19.6% 
21 
100% 
9.1% 
230 
100% 
100% 
 
NB This was an open ended question, coded subsequently. 
 
 
